Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Tight liquidity NBB
Cash and receivables cover 31 % of short-term debt in 2026; threshold 65 %.
Financials
Financial year 2026
PHARMACO from Sint-Niklaas, company number BE0439793050, closed financial year 2026 with a result of € 31 after tax. For that financial year PHARMACO recorded a gross margin of € 291,688 and equity of € 193,513. Compared with financial year 2025, the result moved from € 0 to € 31. Profitable, and profit is growing. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on June 8, 2026.
€ 193,513
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 31
▲ € 31 vs 2025
Profit after tax over the fiscal year.
€ 93,816
▲ 70% vs 2025
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2026. Retained profit grew to € 131,513.
People and assets in 2026
3.6
▼ 0.1 vs 2025
Average over the fiscal year, from the social balance sheet.
€ 239,969
▼ 4% vs 2025
€ 66,700 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 14,612
▼ 21% vs 2025
Book value of vehicles, furniture and equipment.
Debts at end 2026
€ 6,750
▼ 67% vs 2025
Loans from banks and other lenders, long and short.
€ 197,847
▲ 11% vs 2025
Supplier invoices still open on the last day of the fiscal year.
€ 28,911
▲ 1% vs 2025
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2023 | 2024 | 2025 | 2026 | Change 2025 → 2026 | |
|---|---|---|---|---|---|
| Gross margin | € 243,953 | € 289,498 | € 301,939 | € 291,688 | ▼ 3% |
| Profit after taxes | € 1,234 | € 861 | € 0 | € 31 | ▲ € 31 |
| Equity | € 192,620 | € 193,481 | € 193,482 | € 193,513 | |
| Total debts | € 514,613 | € 580,511 | € 384,547 | € 411,192 | ▲ 7% |
| Cash | € 326,122 | € 295,862 | € 55,110 | € 93,816 | ▲ 70% |
| Retained profit | € 130,620 | € 131,481 | € 131,482 | € 131,513 | |
| Bank debt | € 58,306 | € 39,379 | € 20,250 | € 6,750 | ▼ 67% |
| Balance sheet total | € 707,233 | € 773,992 | € 578,029 | € 604,705 | ▲ 5% |
| Employees (FTE) | 3.8 | 3.6 | 3.7 | 3.6 | ▼ 0.1 |
Key figures of PHARMACO, fiscal years 2023 to 2026, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2027) expected before 1 August 2027.
What happened to PHARMACO?
What happened at PHARMACO in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2026: profit of € 31 (▲ € 31 vs 2025). Source: NBB ↗
- DECOPHARMA stepped down as director. NBB
- DECOPHARMA became a director. NBB
- New establishment in Sint-Niklaas. KBO
- Start of the company according to the CBE. KBO
In short
From € 1,234 profit in 2023 to € 31 profit in 2026.
Paid € 23,042 in corporate taxes since 2023.
Best year ever: 2023, with € 1,234 profit.
On average € 81,000 of value added per employee in 2026.
A new publication or filing at PHARMACO? We notify you, reason included.
Follow PHARMACODatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of DECOPHARMA comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
PHARMACOThe shares are held by DECOPHARMA (94.8%).
Directors
According to the 2026 annual accounts
Director · represented by CARLA DE COLVENAER
since 2010 · until 2026
Shareholders
94.8%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Rietvelde 32
9100 Sint-Niklaas
Hertenstraat 104
9100 Sint-Niklaas
Active since 27 February 1990
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0439.793.050
- VAT number
- BE 0439.793.050
- Registered office
- Rietvelde 32, 9100 Sint-Niklaas
- Names & denominations
- PHARMACO
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 27 December 1989
- Peppol
- Active · Active since 29 Aug 2023
- Activities · NACE
Detailhandel in farmaceutische producten
Apothekers